Structure Therapeutics, Inc. Sponsored ADR(GPCR)
$20.95-0.78 (-3.59%)
GPCR
Structure Therapeutics, Inc. Sponsored ADR stock forecast
$20.95
At close:-0.78 (-3.59%)
Want to see GPCR full AI Analyst Report?
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Stock Forecast & Price Target
1,311 Followers
GPCR Analyst Ratings
Strong Buy
10Buy0Hold0Sell
Based on 10 analysts giving stock ratings to Structure Therapeutics, Inc. Sponsored ADR in the past 3 months
GPCR Stock 12 Month Forecast
Average Price Target
$103.67▲(394.83% Upside)Based on 10 Wall Street analysts offering 12 month price targets for Structure Therapeutics, Inc. Sponsored ADR in the last 3 months. The average price target is $103.67 with a high forecast of $145.00 and a low forecast of $70.00. The average price target represents a 394.83% change from the last price of $20.95.
Past 12 Months12 Month ForecastJan2026Oct2026
High$145.00
Average$103.67
Low$70.00
Highest Price TargetHighest$145.00Average Price Target$103.67Lowest Price TargetLowest$70.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Ananda Ghosh | H.C. Wainwright | $70 | buy | 234.13%Upside | Reiterated | 11/12/26 | ||
| Edward Nash | Canaccord Genuity | $111→$107 | buy | 410.74%Upside | Reiterated | 11/10/26 | ||
| Yasmeen Rahimi | Piper Sandler | $93 | buy | 343.91%Upside | Reiterated | 11/10/26 | ||
| Annabel Samimy | Stifel Nicolaus | $90 | buy | 329.59%Upside | Reiterated | 11/10/26 | ||
| Evan Seigerman | BMO Capital | $145 | buy | 592.12%Upside | Reiterated | 11/10/26 | ||
| Kaveri Pohlman | Clear Street | $99 | buy | 372.55%Upside | Reiterated | 09/08/26 | ||
| Andy Hsieh | William Blair | ― | buy | ― | Reiterated | 09/08/26 | ||
| Roger Song | Jefferies | $125 | buy | 496.66%Upside | Reiterated | 09/08/26 | ||
| Patrick Dolezal | LifeSci Capital | $104 | buy | 396.42%Upside | Reiterated | 09/08/26 | ||
| Hardik Parikh | J.P. Morgan | $100 | buy | 377.33%Upside | Reiterated | 08/17/26 | ||
| Samantha Semenkow | Citi | $100→$97 | buy | 363.01%Upside | Reiterated | 08/10/26 | ||
| Terence Flynn | Morgan Stanley | $126 | buy | 501.43%Upside | Assigned | 08/10/26 | ||
| Jonathan Wolleben | Citizens JMP | $113→$110 | buy | 425.06%Upside | Reiterated | 08/07/26 | ||
 Unknown AnalystNot Ranked | Guggenheim | $140 | buy | 568.26%Upside | Reiterated | 08/07/26 | ||
| Prakhar Agrawal | Cantor Fitzgerald | $101 | buy | 382.10%Upside | Reiterated | 06/07/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Ananda GhoshH.C. Wainwright | BuyReiterated$70 | 11/12/26 | 234.13%Upside | ||
| Edward NashCanaccord Genuity | BuyReiterated$111→$107 | 11/10/26 | 410.74%Upside | ||
| Yasmeen RahimiPiper Sandler | BuyReiterated$93 | 11/10/26 | 343.91%Upside | ||
| Annabel SamimyStifel Nicolaus | BuyReiterated$90 | 11/10/26 | 329.59%Upside | ||
| Evan SeigermanBMO Capital | BuyReiterated$145 | 11/10/26 | 592.12%Upside | ||
| Kaveri PohlmanClear Street | BuyReiterated$99 | 09/08/26 | 372.55%Upside | ||
| Andy HsiehWilliam Blair | BuyReiterated | 09/08/26 | ― | ||
| Roger SongJefferies | BuyReiterated$125 | 09/08/26 | 496.66%Upside | ||
| Patrick DolezalLifeSci Capital | BuyReiterated$104 | 09/08/26 | 396.42%Upside | ||
| Hardik ParikhJ.P. Morgan | BuyReiterated$100 | 08/17/26 | 377.33%Upside | ||
| Samantha SemenkowCiti | BuyReiterated$100→$97 | 08/10/26 | 363.01%Upside | ||
| Terence FlynnMorgan Stanley | BuyAssigned$126 | 08/10/26 | 501.43%Upside | ||
| Jonathan WollebenCitizens JMP | BuyReiterated$113→$110 | 08/07/26 | 425.06%Upside | ||
| Unknown AnalystGuggenheimNot Ranked | BuyReiterated$140 | 08/07/26 | 568.26%Upside | ||
| Prakhar AgrawalCantor Fitzgerald | BuyReiterated$101 | 06/07/26 | 382.10%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Structure Therapeutics, Inc. Sponsored ADR
3 Months
Success Rate5/12 ratings generated profit
42%
Average Return
+5.13%
Copying Andy Hsieh's trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of +5.13% per trade.
1 Year
Success Rate8/17 ratings generated profit
47%
Average Return
+27.41%
Copying Ananda Ghosh's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of +27.41% per trade.
2 Years
Success Rate8/20 ratings generated profit
40%
Average Return
-8.91%
Copying Jonathan Wolleben's trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of -8.91% per trade.
GPCR Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 8 | 15 | 17 | 17 | 10 |
| Buy | 3 | 4 | 3 | 3 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 11 | 19 | 20 | 20 | 11 |
In the current month, GPCR has received 11 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. GPCR average Analyst price target in the past 3 months is 103.67.
GPCR Financial Forecast
High$-0.50
Consensus$-0.65
Low$-0.75
GPCR Earnings Forecast
Next quarter’s earnings estimate for GPCR is -$0.65 with a range of -$0.75 to -$0.50. The previous quarter’s EPS was -$0.66. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$0.00
Consensus$0.00
Low$0.00
GPCR Sales Forecast
Next quarter’s sales forecast for GPCR is $0 with a range of $0 to $0. The previous quarter’s sales results were $0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
GPCR Stock Forecast FAQ
What is GPCR’s average 12-month price target, according to analysts?
Based on analyst ratings, Structure Therapeutics, Inc. Sponsored ADR’s 12-month average price target is $103.67.
What is GPCR’s upside potential, based on the analysts’ average price target?
Structure Therapeutics, Inc. Sponsored ADR has 394.83% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GPCR a Buy, Sell or Hold?
Structure Therapeutics, Inc. Sponsored ADR has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
What is Structure Therapeutics, Inc. Sponsored ADR’s price target?
The average price target for Structure Therapeutics, Inc. Sponsored ADR is $103.67. This is based on 10 12-month price targets, issued in the past 3 months. The highest analyst price target is $145.00, the lowest forecast is $70.00. The average price target represents a 394.83% increase from the current price of $20.95.
What do analysts say about Structure Therapeutics, Inc. Sponsored ADR?
Structure Therapeutics, Inc. Sponsored ADR’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Street analysts.
How can I buy shares of GPCR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
